Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zipalertinib plus chemotherapy vs chemotherapy in first-line EGFR exon 20 insertion mutant non-squamous NSCLC
CTR20240690Phase 3Active
- Sponsor
- Taiho Oncology
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Taiho Oncology. Primary endpoint: Progression-free survival (PFS) by BICR. Started Apr 2024; status: active.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240690.